Bioequivalence of Drugs Containing Maidenhair Tree (EGB 761)

K.F. Trinus

Abstract


The paper deals with the items of bioeqivalency of various drugs containing ginkgo biloba as well as estimates the effectiveness of treatment with different nootropic agents. There are considered the studies of Tanakan (EGb 761) effectiveness for the cure of moderate cognitive disorders and the results of the international investigations, including Cochraine reports. There are described the results of study of quantitative and qualitive composition of some agents of ginkgo biloba, particularly the original medication Tabakan (EGb 761). The demonstrated results confirms the significant variation in composition of drugs containing ginkgo biloba on the Ukrainian market.


Keywords


moderate cognitive disorders; memory; bioequivalence; Tanakan

References


Atzori C., Bruno A., Chichino G., Bombardelli E., Scaglia M., Ghione M. Activity of bilobalide, a sesquiterpene from Ginkgo biloba, on Pneumocystis carinii // Antimicrob. Agents Chemother. — 1993 Jul. — 37 (7). — 1492-1496. PMCID: PMC188000.

Barrett M. The Handbook of Clinically Tested Herbal Re-medies 9780789027238.

Bauer U. Six month double-blind randomized clinical trial of Ginkgo biloba extract versus placebo in two parallel groups in patients suffering from peripheral arterial insufficiency // Arzneimittel-Forschung. — 1984. — 34. — 716-720,

Birkett D.J. Generics — equal or not? // Aust. Prescr. — 2003. — 26. — 85-7.

Blume J. et al. Placebokontrollierte Doppelblindstudie zur Wirksamkeit von Ginkgo biloba-Spezialextrakt EGb 761 bei austrainierten Patienten mit Claudicatio intermittens // VASA. — 1996. — 2. — 1-11.

Brust P. Reversal of scopolamine-induced alterations of choline transport across the blood-brain barrier by the nootropics piracetam and pramiracetam // Arzneim.-Forsch. Drug Rex. — 1989. — 39. — 1220-1222.

Buell J.S., Scott T.M., Dawson-Hughes B., Dallal G.E., Rosenberg I.H., Folstein M.F., Tucker K.L. Vitamin D is associated with cognitive function in elders receiving home health services // J. Gerontol. a Biol. Sci. Med. Sci. — Aug 2009. — 64, 8. — 888-95. doi: 10.1093/gerona/glp032. PMC 2981461. PMID 19377013.

Center for Drug Evaluation and Research (2003). Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products — General Considerations. United States Food and Drug Administration.

Cohen A.J., Bartlik B. Ginkgo biloba for antidepressant-induced sexual dysfunction // J. Sex Marital. Ther. — 1998 Apr-Jun. — 24 (2). — 139-43.

Colovic M.B., Krstic D.Z., Lazarevic-Pasti T.D., Bondzic A.M., Vasic V.M. Acetylcholinesterase Inhibitors: Pharmaco­logy and Toxicology // Current Neuropharmacology. — 2013. — 11, 3. — 315-335. doi: 10.2174/1570159X11311030006.

Committee for Medicinal Products for Human Use (20 January 2010). Guideline on the Investigation of Bioequivalence. European Medicines Agency. Retrieved 21 April 2011.

Corasaniti M.T., Paoletti A.M., Palma E., Granato T., Navarra M., Nistico G. Systemic Administration of Pramiracetam increases Nitric Oxide Syntase Activity in the Cerebral Cortex of the Rat // Functional Neurology. — 1995. — 10, 3. — 151-155.

DeFeudis F.V. Ginkgo biloba extract (egb 761): pharmacological activities and clinical applications. — Paris: Elsevier, Editions Scientifiques, 1991. — 1187 р.

Dimpfel W., Wedekind W., Keplinger I. Efficacy of dimethy-laminoethanol (DMAE) containing vitamin-mineral drug combination on EEG patterns in the presence of different emotional states // Eur. J. Med. Res. — May 2003. — 8, 5. — 183-91. PMID 12844472.

Fioravanti M., Buckley A.E. Citicoline (Cognizin) in the treatment of cognitive impairment // Clin. Interv. Aging. — Sep 2006. — 1, 3. — 247-251. PMCID: PMC2695184.

Gleason C.E., Carlsson C.M., Barnet J.H., Meade S.A., Setchell K.D., Atwood C.S., Johnson S.C., Ries M.L., Asthana S. A preliminary study of the safety, feasibility and cognitive efficacy of soy isoflavone supplements in older men and women // Age Ageing. — January 2009. — 38, 1. — 86-93. doi: 10.1093/ageing/afn227. PMC 2720778. PMID 19054783.

Gower A.J., Tricklebank M.D., The effects of cholinergic drugs support an avoidance learning hypothesis of brief foot shock-induced analgesia // Neuropharmacology. — 1986. — 25. — 1161-1166.

Haguenauer J.P. et al. Traitement des troubles de l’equilibre par l’extrait de Ginkgo biloba // Presse medicale. — 1986. — 15. — 1569-1572.

Heishman S.J., Kleykamp B.A., Singleton E.G. Meta-analysis of the acute effects of nicotine and smoking on human performance // Psychopharmacology (Berl.). — June 2010. — 210, 4. — 453-69. doi: 10.1007/s00213-010-1848-1. PMC 3151730. PMID 20414766. Retrieved March 23, 2012.

Hong Z., Moessler H., Bornstein N., et al. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of cerebrolysin in patients with acute ischemic stroke in Asla-Casta // Int. J. Stroke. — 2009. — 4. — 406-412.

Jia X., McNeill G., Avenell A. Does taking vitamin, mineral and fatty acid supplements prevent cognitive decline? A systematic review of randomized controlled trials // J. Hum. Nutr. Diet. — August 2008. — 21, 4. — 317-336. doi: 10.1111/j.1365-277X.2008.00887.x. PMID 18721399.

Kampkötter A., Nkwonkam C.G., Zurawski R.F., Timpel C., Chovolou Y., Wätjen W., Kahl R. Investigations of protective effects of the flavonoids quercetin and rutin on stress resistance in the model organism Caenorhabditis elegans // Toxicology. — 2007 May 5. — 234 (1–2). — 113-23. Epub 2007 Feb 21. PMID: 17376580 [PubMed — indexed for MEDLINE].

Kaschel R. Ginkgo biloba: specificity of neuropsychological improvement — a selective review in search of differential effects // Human Psychopharmacol. — 2009. — 24, 5. — 345-370. doi: 10.1002/hup.1037. PMID 19551805.

Kennedy D.O., Wightman E.L. Herbal extracts and phytochemicals: plant secondary metabolites and the enhancement of human brain function // Adv. Nutr. — Jan 2011. — 2, 1. — 32-50. doi: 10.3945/an.110.000117. PMID 22211188.

Knobel M. Approach to a combined pharmacologic therapy of childhood hyperkinesis // Behav. Neuropsychiatry.— 1974. — 6. — 1-12, 87-90. PMID 4619768.

Kressmann S., Muller W.E., Blume H.H. Pharmacological quality of different Ginkgo biloba brands // J. of Pharmacy & Pharmacol. — 2002. — 54. — 661-669.

Li F., Tsien J.Z. Memory and the NMDA receptors // N. Engl. J. Med. — 2009. — 361, 3. — 302-303. doi: 10.1056/NEJMcibr0902052. PMC 3703758. PMID 19605837.

Li R., Chen B., Wu W., Bao L., Li J. et al. Ginkgolide B suppresses intercellular adhesion molecule-1 expression via blocking nuclear factor-kB activation in human vascular endothelial cells stimulated by oxidized low-density lipoprotein // J. Pharmacol. Sci. — 2009. — 110. — 362-9 [PubMed].

Liu X., Zhao G., Yan Y., Bao L., Chen B. et al. Ginkgolide B reduces atherogenesis and vascular inflammation in ApoE−/− mice // PLoS One. — 2012. — 7. — e36237. [PMC free article] [PubMed].

Malenka R.C., Nestler E.J., Hyman S.E. Chapter 13: Higher Cognitive Function and Behavioral Control // Sydor A., Brown R.Y. Molecular Neuropharmacology: A Foundation for Clinical Neuroscience. — 2nd ed. — New York: McGraw-Hill Medical, 2009. — 318 p.

Ma L., Liu X., Zhao Y., Chen B., Li X. and Qi R. Ginkgolide B Reduces LOX-1 Expression by Inhibiting Akt Phosphorylation and Increasing Sirt1 Expression in Oxidized LDL-Stimulated Human Umbilical Vein Endothelial Cells // PLoS One. — 2013; 8 (9). — e74769. Published online 2013 Sep 17. doi: 10.1371/journal.pone.0074769 PMCID: PMC3775799.

Manor I., Magen A., Keidar D., Rosen S., Tasker H., Cohen T., Richter Y., Zaaroor-Regev D., Manor Y., Weizman A. The effect of phosphatidylserine containing Omega3 fatty-acids on attention-deficit hyperactivity disorder symptoms in children: a double-blind placebo-controlled trial, followed by an open-label extension // Eur. Psychiatry. — July 2012. — 27, 5. — 335-342. doi: 10.1016/j.eurpsy.2011.05.004. PMID 21807480.

McLean A.Jr, Cardenas D.D., Burgess D., Gamzu E. Placebo-controlled study of pramiracetam in young males with memory and cognitive problems resulting from head injury and anoxia // Brain Inj. — 1991 Oct-Dec. — 5, 4. — 375-380. PMID: 1786500.

Mereu M., Bonci A., Newman A.H., Tanda G. The neurobiology of modafinil as an enhancer of cognitive performance and a potential treatment for substance use disorders // Psychopharmaco-logy (Berl.). — October 2013. — 229, 3. — 415-434. doi: 10.1007/s00213-013-3232-4. PMID 23934211.

Miller G.M. The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity // J. Neurochem. — January 2011. — 116, 2. — 164-176. doi:10.1111/j.1471-4159.2010.07109.x. PMC 3005101. PMID 21073468.

Mori K., Inatomi S., Ouchi K., Azumi Y., Tuchida T. Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial // Phytotherapy Research. — March 2009. — 23, 3. — 367-372. doi:10.1002/ptr.2634. PMID 18844328.

Moskaug J.Ø., Carlsen H., Myhrstad M., Blomhoff R. Molecular imaging of the biological effects of quercetin and quercetin-rich foods // Mech. Ageing Dev. — 2004 Apr. — 125 (4). — 315-24. PMID:15063108.

Moss F., Ward L.M., Sannita W.G. Stochastic resonance and sensory information processing: a tutorial and review of application // Clin. Neurophysiol. — 2004. — 115. — 267-281.

Műller W.E., Stoll L., Schubert T., Gelbmann C.M. Central cholinergic functioning and aging // Acta Psychiatr Scand. Suppl. — 1991. — 366. — 34-39.

Neis A.S. Principles of therapeutics // The pharmacological basis of therapeutics / Ed. by Gudman Gillman A., Roll T.W., Nies A.S., Taylor P. — 8th edition. — NY: McGrow-Hill., Inc. NY, 1993. — 62-83.

Norwegian Medicines Control Authority. The Norwegian guidelines for pharmacoeconomical analysis in connection with application for reimbursement. Norwegian Medicines Control Authority Department of Pharmacoeconomics. Oslo, 1999.

O’Neill M.J., Bleakman, D., Zimmerman D.M., Nisenbaum E.S. AMPA Receptor Potentiators for the Treatment of CNS Disorders. Current Drug Targets // CNS and Neurological Disorders. — 2004. — 3, 3. — 181-194. doi: 10.2174/1568007043337508. PMID 15180479.

Orliewska E., Mierzejewski P. Guidelines for conducting pharmacoeconomic evaluations // Farm. Econ. — 2000. — Suppl. 1.

Pase M.P., Kean J., Sarris J., Neale C., Scholey A.B., Stough C. The cognitive-enhancing effects of Bacopa monnieri: a systematic review of randomized, controlled human clinical trials // The Journal of Alternative and Complementary Medicine. — July 2012. — 18, 7. — 647-652. doi:10.1089/acm.2011.0367. PMID 22747190. Retrieved March 27.

Pugsley T.A., Shih Y.H., Coughenour L., Stewart S.F. Some neurochemical properties of pramiracetam (CI-879), a new cognition-enhancing agent // Drug Development Research [Internet]. — 1983 Apr 26 [cited 2012 Mar 28]. — 3. — 407-420.

Riteco J.A., de Heij I.J.M., van Luijn J.C.F. Dutch guidelines for pharmacoeconomic research. — Amstelveen: College voor Zorgverzekeringen, 1999.

Rogers P. Caffeine, mood and mental performance in everyday life // Psychology Today. — 2007. — 32, 1. — 84-89. doi: 10.1111/j.1467-3010.2007.00607.x.

Saudreau F., Serise J.M., Pillet J. Efficacitй de l’extrait de Ginkgo biloba dans le traitement des artйriopathies obliterantes chroniques des membres inferieurs au stade III de la classification de Fontaine // Journal malade vasculare. — 1989. — 14. —177- 182.

Klaus-Peter Schwabe. Method of preparation of an extract from Ginkgo biloba leaves and pharmaceuticals containing the extract. U.S. Patent US5322688, issued July, 1989.

Selhub J., Bagley L., Miller J., Rosenberg I. B vitamins, homocysteine, and neurocognitive function in the elderly // American Journal of Clinical Nutrition. — 2000. — 71, 2. — 614S-620S. PMID 10681269.

Sticher O. Quality of Ginkgo preparations // Planta medica. — 1993. — 59. — 2-11

Tadashi Y., Kunio K., Futoshi M., Nobuhiro K., Hiroshi K., Daisuke T. Specific Inhibitors for Prolyl Endopeptidase and their Anti-amnestic Effect // J. Pharmacobio-Din. — 1987. — 10. — 730-735.

Thorp A., Sinn N., Buckley J., Coates A., Howe P. Soya isoflavone supplementation enhances spatial working memory in men // Br. J. Nutr. (NLM). — Nov 2009. — 102, 9. — 1348-1354. doi:10.1017/S0007114509990201. PMID 19480732. Retrieved March 24, 2014.

Trinus K. Vestibular system: morpho-physiology and patho-logy. — Lambert Academic Publishing. 2012. — 544 p.

Wang S.J., Chen H.H. Ginkgolide B, a constituent of Ginkgo biloba, facilitates glutamate exocytosis from rat hippocampal nerve terminals // Eur. J. Pharmacol. — 2005 May. — 9, 514 (2–3). — 141-9. Pubmed.

Zhang S., Chen B., Wu W., Bao L., Qi R. Ginkgolide B reduces inflammatory protein expression in oxidized low-density lipoprotein-stimulated human vascular endothelial cells // J. Cardiovasc. Pharmacol. — 2011. — 57. — 721-7 [PubMed].

Zs-Nagy I. On the role of intracellular physicochemistry in quantitative gene expression during aging and the effect of centrophenoxine. A review // Archives of gerontology and geriatrics. — 1989. — 9, 3. — 215-229.

http://peaknootropics.com/category/general/page/3/




DOI: https://doi.org/10.22141/2224-0713.7.77.2015.78144

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 INTERNATIONAL NEUROLOGICAL JOURNAL

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru